Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

421. Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery

Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events (...) after infrainguinal bypass surgery Tangelder M J, Lawson J A, Algra A, Eikelboom B C Authors' objectives To determine the efficacy of antiplatelet therapy and oral anticoagulants in maintaining graft patency and preventing ischemic complications in patients after infrainguinal bypass surgery. Searching MEDLINE was searched from 1966 onwards using the keywords 'aspirin', 'acetylsalicylic acid', 'antiplatelet', '(oral) anticoagulants', 'anticoagulation', 'phenprocoumon', 'warfarin', 'peripheral

DARE.1999

422. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis

Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis Hart R G, Benavente O, Pearce L A Authors' objectives To determine whether the addition of aspirin to oral anti- coagulation increases the risk of intracranial (...) haemorrhage. Searching Studies were sought from the following sources: MEDLINE combining the keywords 'aspirin, anticoagulation, and clinical trials' (1990 to 1997); Antithrombotic Trialists' Collaboration; and through searching the reference lists of the proceedings of a major consensus conference on antithrombotic therapy. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) which tested aspirin in addition to oral anticoagulation with vitamin K

DARE.1999

423. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: aspirin, dipyridamole and aspirin-dipyridamole

Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: aspirin, dipyridamole and aspirin-dipyridamole Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: aspirin, dipyridamole and aspirin-dipyridamole Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: aspirin, dipyridamole and aspirin-dipyridamole Chambers M, Hutton J, Gladman J Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antiplatelet therapies, specifically aspirin, dipyridamole and a combination of the two, in the prevention of recurrent stroke, myocardial infarction and other vascular events in patients who have

NHS Economic Evaluation Database.1999

424. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin.

Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. 10514159 1999 11 19 1999 11 19 2014 06 15 0959-8138 319 7215 1999 Oct 09 BMJ (Clinical research ed.) BMJ Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. 958-64 To investigate (...) the effectiveness of aspirin and coumarin in preventing thromboembolism in patients with non-rheumatic atrial fibrillation in general practice. Randomised controlled trial. 729 patients aged >/=60 years with atrial fibrillation, recruited in general practice, who had no established indication for coumarin. Mean age was 75 years and mean follow up 2. 7 years. Primary care in the Netherlands. Patients eligible for standard intensity coumarin (international normalised ratio 2.5-3.5) were randomly assigned

BMJ1999 Full Text: Link to full Text with Trip Pro

425. Aspirin for the secondary prophylaxis of vascular disease in primary care

Aspirin for the secondary prophylaxis of vascular disease in primary care Aspirin for the secondary prophylaxis of vascular disease in primary care Aspirin for the secondary prophylaxis of vascular disease in primary care University of Newcastle upon Tyne. Centre for Health Services Research; University of York. Centre for Health Economics Authors' objectives To provide evidence linked recommendations for general practitioners on the use of aspirin for the secondary prophylaxis of nonfatal (...) reviews, meta-analyses, randomised trials, quality of life studies and economic studies with follow-up ranging from 2 to 4 years. Specific interventions included in the review Aspirin (75 to 150 mg/day) and other antiplatelet therapies. Participants included in the review Patients at risk of cardiovascular disease or stroke including actual and suspected acute myocardial infarction (MI), previous MI, stable angina, unstable angina, past history of stoke or transient ischaemic attack, and intermittent

DARE.1998

426. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials

Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials He J, Whelton P K, Vu B, Klag M J Authors' objectives To estimate the risk of haemorrhagic stroke associated with aspirin treatment. Searching MEDLINE was searched from 1966 through June 1997 for articles published in the English (...) language using the keywords 'aspirin' and 'cerebrovascular disorders', as well as 'stroke'. Articles retrieved were those identified in the database as clinical trials on human subjects. A manual search was preformed using the authors' reference files and reference lists from original communications and review articles. Study selection Study designs of evaluations included in the review Studies were included if they fulfilled the following criteria: random allocation to aspirin or concurrent control

DARE.1998

427. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants

A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible case for oral anticoagulants A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy: equivalence of costs as a possible (...) case for oral anticoagulants Gianetti J, Gensini G, De Caterina R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Aspirin (antiplatelet) and warfarin (anticoagulant) for the prevention of coronary artery disease after acute

NHS Economic Evaluation Database.1998

428. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.

Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. 9494145 1998 03 12 1998 03 12 2013 11 21 0028-4793 338 11 1998 Mar 12 The New England journal of medicine N. Engl. J. Med. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. 701-5 Whether low-dose aspirin prevents (...) pregnancy. The women were enrolled between gestational weeks 13 and 26 and received either 60 mg of aspirin or placebo daily. Outcome data were obtained on all but 36 of the 2539 women who entered the study. The incidence of preeclampsia was similar in the 1254 women in the aspirin group and the 1249 women in the placebo group (aspirin, 18 percent; placebo, 20 percent; P=0.23). The incidences in the aspirin and placebo groups for each of the four high-risk categories were also similar: for women

NEJM1998

429. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 9563981 1998 06 03 1998 06 03 2014 06 17 0959-8138 316 7141 1998 May 02 BMJ (Clinical research ed.) BMJ ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral (...) aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 1337-43 To assess effects of intravenous streptokinase, one month of oral aspirin, or both, on long term survival after suspected acute myocardial infarction. Randomised, "2 x 2 factorial," placebo controlled trial. 417 hospitals in 16 countries. 17 187 patients with suspected acute myocardial infarction randomised between March 1985 and December 1987. Follow up of vital status complete

BMJ1998 Full Text: Link to full Text with Trip Pro

430. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research

Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research 9457092 1998 02 19 1998 02 19 2015 06 16 0140-6736 351 9098 1998 Jan 24 Lancet (London, England) Lancet Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary (...) prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. 233-41 We aimed to evaluate low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease (IHD). 5499 men aged between 45 years and 69 years at high risk of IHD were recruited from 108 practices in the UK that belong to the Medical Research Council's General Practice Research Framework. Initially, warfarin

Lancet1998

431. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 9635947 1998 07 10 1998 07 10 2015 06 16 0140-6736 351 9118 1998 Jun 13 Lancet (London, England) Lancet Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 1755-62 (...) Despite treatment, there is often a higher incidence of cardiovascular complications in patients with hypertension than in normotensive individuals. Inadequate reduction of their blood pressure is a likely cause, but the optimum target blood pressure is not known. The impact of acetylsalicylic acid (aspirin) has never been investigated in patients with hypertension. We aimed to assess the optimum target diastolic blood pressure and the potential benefit of a low dose of acetylsalicylic acid

Lancet1998

432. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. 9599104 1998 05 21 1998 05 21 2014 11 20 0028-4793 338 21 1998 May 21 The New England journal of medicine N. Engl. J. Med. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. 1498-505 Activation (...) of platelets is central to the pathophysiology of unstable angina. We studied whether inhibition of the final common pathway for platelet aggregation with tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist, would improve clinical outcome in this condition. In a double-blind study, we randomly assigned 3232 patients who were already receiving aspirin to additional treatment with intravenous tirofiban for 48 hours. The primary end point was a composite of death, myocardial infarction

NEJM1998

433. Aspirin in the primary prevention of cardiovascular disease and colon cancer

Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Aspirin in the primary prevention of cardiovascular disease and colon cancer Hailey D, Harstall C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hailey D, Harstall C. Aspirin in (...) the primary prevention of cardiovascular disease and colon cancer. Alberta Heritage Foundation for Medical Research (AHFMR) 1997: 25 Authors' objectives To assess the evidence of effectiveness and safety in the prophylactic use of acetylsalicylic acid in the primary prevention of myocardial infarction, stroke and colon cancer. Authors' conclusions There is insufficient evidence to support the prophylactic use of ASA in the general population to reduce the risk of myocardial infarction, stroke and colon

Health Technology Assessment (HTA) Database.1997

434. Combined aspirin and metoclopramide in the acute treatment of migraine attacks: a review

Combined aspirin and metoclopramide in the acute treatment of migraine attacks: a review Combined aspirin and metoclopramide in the acute treatment of migraine attacks: a review Combined aspirin and metoclopramide in the acute treatment of migraine attacks: a review Chabriat H, Danchot J, Hugues F C, Joire J E Authors' objectives To review all the trials evaluating the efficacy of combined aspirin and metoclopramide (CAM) in the acute treatment of migraine attacks. Searching MEDLINE (...) and Excerpta Medica were searched from 1975 to 1996. No search terms were provided. Study selection Study designs of evaluations included in the review Both open and double-blind trials were included in the review. No details were provided of the method used to allocate the patients to the groups. Uncontrolled studies were also included. Specific interventions included in the review The combination of oral aspirin (in doses ranging from 650 to 900 mg) and oral metoclopramide (10 mg per dose) was compared

DARE.1997

435. Do codeine and caffeine enhance the analgesic effect of aspirin: a systematic overview

Do codeine and caffeine enhance the analgesic effect of aspirin: a systematic overview Do codeine and caffeine enhance the analgesic effect of aspirin: a systematic overview Do codeine and caffeine enhance the analgesic effect of aspirin: a systematic overview Zhang W Y, Li Wan Po A Authors' objectives To assess whether codeine and caffeine enhance the analgesic effect of aspirin in post-operative pain. Searching Computerised searches of MEDLINE and BIDS (EMBASE and ISI databases) were (...) were included. The observation period in the trials ranged from 2 to 12 hours. Studies were excluded on the basis of the following: relevant data were not extractable; there was self-controlled dose adjustment; syrup or buffered formulations were used; or the report of the trial was unobtainable. Abstracts and reports from multi-dose trials were also excluded. Specific interventions included in the review Oral formulations of aspirin, aspirin and codeine, aspirin and caffeine, and placebo

DARE.1997

436. A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation

A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation A meta-analysis of low dose aspirin for the prevention of intrauterine growth retardation Leitich H, Egarter C, Husslein P, Kaider A, Schemper M Authors' objectives To determine more precisely the effect of prophylactic low-dose aspirin on intra-uterine growth retardation and perinatal mortality. Searching Eighteen (...) medical databases including MEDLINE (from 1964 onwards) and EMBASE (from 1974 onwards) were searched using the terms 'acetylsalicylic acid', 'aspirin', 'pregnancy', 'randomised' and 'meta-analysis'. References from retrieved reports and review articles were also examined. Only reports published in the English language were considered. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of aspirin alone or in combination with another antiplatelet

DARE.1997

437. Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia.

Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. 9357405 1997 11 26 1997 11 26 2015 06 16 0140-6736 350 9087 1997 Nov 01 Lancet (London, England) Lancet Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. 1267-71 Pre-eclampsia is associated with extensive endothelial-cell damage and platelet activation, resulting in lower production of vasodilator prostaglandins and increased release of the vasoconstrictors thromboxane A2 (...) ' gestation. 69 women received ketanserin and 69 received placebo. Both groups also received aspirin. Patients were initially given two tablets daily, increased to four tablets daily in diastolic blood pressure was more than 90 mm Hg. Primary outcomes were the development of pre-eclampsia and severe hypertension, and perinatal mortality. There were significantly fewer cases of pre-eclampsia (two vs 13; relative risk 0.15 [95% CI 0.04-0.66], p = 0.006) and severe hypertension (six vs 17; p = 0.02

Lancet1997

438. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) 9022487 1997 03 07 1997 03 07 2013 11 21 0959-8138 314 7076 1997 Jan 25 BMJ (Clinical research ed.) BMJ Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) 253-7 To determine whether (...) treatment with low dose aspirin and heparin leads to a higher rate of live births than that achieved with low dose aspirin alone in women with a history of recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies), lupus anticoagulant, and cardiolipin antibodies (or anticardiolipin antibodies). Randomised controlled trial. Specialist clinic for recurrent miscarriages. 90 women (median age 33 (range 22-43)) with a history of recurrent miscarriage (median number 4

BMJ1997 Full Text: Link to full Text with Trip Pro

439. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.

The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. 9174558 1997 06 17 1997 06 17 2015 06 16 0140-6736 349 9065 1997 May 31 Lancet (London, England) Lancet The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial (...) Collaborative Group. 1569-81 Only a few small trials have compared antithrombotic therapy (antiplatelet or anticoagulant agents) versus control in acute ischaemic stroke, and none has been large enough to provide reliable evidence on safety or efficacy. The International Stroke Trial (IST) was a large, randomised, open trial of up to 14 days of antithrombotic therapy started as soon as possible after stroke onset. The aim was to provide reliable evidence on the safety and efficacy of aspirin and

Lancet1997

440. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. 9077376 1997 04 08 1997 04 08 2013 11 21 0028-4793 336 14 1997 Apr 03 The New England journal of medicine N. Engl. J. Med. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. 973-9 Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin (...) decreases the risk. We measured plasma C-reactive protein, a marker for systemic inflammation, in 543 apparently healthy men participating in the Physicians' Health Study in whom myocardial infarction, stroke, or venous thrombosis subsequently developed, and in 543 study participants who did not report vascular disease during a follow-up period exceeding eight years. Subjects were randomly assigned to receive aspirin or placebo at the beginning of the trial. Base-line plasma C-reactive protein

NEJM1997